Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS‐ONE trial

Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS‐ONE trial

Abstract Aims A multicentre trial, ICOS‐ONE, showed increases above the upper limit of normality of cardiac troponin (cTn) in 27% of patients within 12 months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with enalapril was started at study entry in all (p...

Full description

Bibliographic Details
Main Authors: Jennifer M.T.A. Meessen, Daniela Cardinale, Fabio Ciceri, Maria Teresa Sandri, Maurizio Civelli, Barbara Bottazzi, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Gianluigi Condorelli, Enrico Barbieri, Stefania Gori, Alessandro Colombo, Giuseppe Curigliano, Michela Salvatici, Paolo Pastori, Francesco Ghisoni, Alessandra Bianchi, Cristina Falci, Pietro Cortesi, Alberto Farolfi, Anna Monopoli, Carlo Milandri, Marco Bregni, Alessandra Malossi, Daniele Nassiacos, Claudio Verusio, Lidia Staszewsky, Roberto Leone, Deborah Novelli, Giovanna Balconi, Enrico B. Nicolis, Maria Grazia Franzosi, Serge Masson, Cecilia Garlanda, Alberto Mantovani, Carlo M. Cipolla, Roberto Latini, ICOS‐ONE Study Investigators
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:ESC Heart Failure
Subjects:
Cardio‐oncology
Anthracyclines
Troponin
Echocardiography
Biomarkers
Cardiac dysfunction
Online Access:https://doi.org/10.1002/ehf2.12695

Internet

https://doi.org/10.1002/ehf2.12695

Similar Items